Advances in Precision Medicine in Lung Cancer

Clinicians discuss data on the ROS1 TKI taletrectinib in patients with locally advanced or metastatic ROS1-positive non–small cell lung cancer.

Alexander Drilon, MD, discusses the potential benefit of taletrectinib in patients with ROS1-positive non–small cell lung cancer.

Jason Porter, MD, discusses the potential role of the next-generation TKI taletrectinib in patients with ROS1-positive non–small cell lung cancer, according to data from the phase 2 TRUST-II trial.

Heather Wakelee, MD, FASCO, discusses the significance of early data on the use of taletrectinib in patients with ROS1-positive non–small cell lung cancer from the phase 2 TRUST-II trial.

Stephen V. Liu, MD, discusses the interim analysis of the phase 2 TRUST-II trial, which is investigating the use of taletrectinib in patients with ROS1-positive non–small cell lung cancer.

D. Ross Camidge, MD, PhD, discusses the rationale for the ongoing phase 2 TRUST-II trial of taletrectinib in patients with non–small cell lung cancer harboring ROS1 mutations.